Trials / Completed
CompletedNCT00120055
Association Between Systemic Exposure of Atorvastatin and Metabolites and Atorvastatin-induced Myotoxicity
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- University of Oslo School of Pharmacy · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to investigate whether the pharmacokinetics of atorvastatin and/or its metabolites is altered in patients with confirmed atorvastatin-induced myopathy compared to healthy controls.
Detailed description
A 24 hour pharmacokinetic investigation of atorvastatin and metabolites will be performed in 15 patients with a history of atorvastatin -induced myotoxicity. The possible link to relevant mutations in SLCO1B1, CYP3A5 and MDR1 will be also be investigated
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Atorvastatin (Lipitor) |
Timeline
- Start date
- 2005-02-01
- Completion
- 2005-04-01
- First posted
- 2005-07-14
- Last updated
- 2014-12-03
Source: ClinicalTrials.gov record NCT00120055. Inclusion in this directory is not an endorsement.